Lilly's Zepbound® Launch: Strategic Positioning in Obstructive Sleep Apnea Market

Lilly's Zepbound® Launch: Strategic Positioning in Obstructive Sleep Apnea Market | Eli Lilly Intelligence | Humanexa

Evidence Sources

Source-backed references used to construct this page.

Research: National Commission into the Regulation of AI in Healthcare: research, engagement and call for evidence findings
MHRA
FDA document
View source
Promotional material: National AI Commission: Ask Me Anything
MHRA
FDA document
View source
Azuma Foods International, Inc.
FDA
FDA document
View source
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
ClinicalTrials.gov
FDA document
View source
L-Citrulline and Tadalafil for Mild to Moderate Erectile Dysfunction
ClinicalTrials.gov
FDA document
View source
Sleep Disturbance and Relapse in Individuals With Alcohol Dependence: An Exploratory Mixed Methods Study
ClinicalTrials.gov
FDA document
View source
tDCS: Sleep to Mood in Depression (S2M-D)
ClinicalTrials.gov
FDA document
View source
Multidimensional Sleep Health Intervention for Couples
ClinicalTrials.gov
FDA document
View source
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
ClinicalTrials.gov
FDA document
View source
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
ClinicalTrials.gov
FDA document
View source
FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
Lilly
FDA document
View source
Bristol Myers Squibb to be Inaugural Partner for Life Science Cares National Campaign to Advance Health Equity and Fight Food Insecurity
Bristol Myers Squibb
FDA document
View source
A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from Dutch societal perspective.
PubMed
FDA document
View source
Burden of HPV-associated cancers in Peruvian men: Evidence from national health data.
PubMed
FDA document
View source
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.
PubMed
FDA document
View source
Safety and immunogenicity of a booster dose of COVAC-2, Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre tria
PubMed
FDA document
View source
NMR detects clustering and ultra-weak excipient interactions governing monoclonal antibody viscosity in formulation-relevant conditions.
PubMed
FDA document
View source
Lilly's Zepbound® (tirzepatide) targets moderate obstructive sleep apnea in national campaign with Shaquille O'Neal
Lilly
FDA document
View source
Lilly's Zepbound® (tirzepatide) targets moderate obstructive sleep apnea in national campaign with Shaquille O'Neal
Lilly Investor Relations
FDA document
View source

Lilly's Zepbound® Launch: Strategic Positioning in Obstructive Sleep Apnea Market

Asset Overview

Company Context

Regulatory Timeline

Related Signals

Evidence Sources